CD8A and graft versus host disease: The control SLE group (No Rx) had the highest GVHD score (Figure 2D, two-way ANOVA interaction, Time and Group; p < 0.0001), circulating human CD45+ cells (Figure 2E, p < 0.05), and circulating human CD8+ T cells (Figure 2F, p < 0.05), when compared to either of the treatment arms (Rux, UCB-Treg, and UCB-Treg+Rux).